ASH 2018 | ZUMA-1 update: safety data of axi-cel in patients with R/R DLBCL

Sattva Neelapu

In the pivotal ZUMA-1 study (NCT02348216), the efficacy outcomes in patients either younger than 65 years or 65 years and older receiving axicabtagene ciloleucel (axi-cel) CD19 CAR T-cell therapy for relapsed/ refractory diffuse large B-cell lymphoma (DLBCL) were comparable. Here, Sattva Neelapu, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the previously unknown safety outcomes of this therapy, revealing the similar response rates between the elderly and younger age groups, with comparable toxicities. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video